2%) undergoing boceprevir triple therapy achieved an EVR (59 5% m

2%) undergoing boceprevir triple therapy achieved an EVR (59.5% male, 32.9% > 50 years, 61.8% with baseline viral load > 400.000 IU/mL) while 64 patients (28.8%) did not (48.4% male, 48.4% > 50 years, 82.8% with baseline viral load > 400.000 FK866 nmr IU/mL). As shown in the table pts with normal gamma-GT values had a higher virologic response >1log10 to PegIFN/RBV lead-in at the end of TW4. In addition there was a significant higher virologic response

in pts who achieved EVR. Only 1 patient (0.8%) with EVR had HCV-RNA levels > 100 IU/mL thereby fulfilling TW12 stopping rules in contrast to 9 pts (9.2%) without EVR. A better virologic response was found at TW24 and at the end of treatment (EOT) with EOT response rates of 94.9% and 65.9% in pts with and without EVR. Until yet Dabrafenib documented follow-up data were available from 72 pts with EOT response: In the subgroup of pts with EVR, 57/63 (90.5%) achieved SVR and 4 pts had a documented relapse (6.3%) while 9 pts without EVR but EOT response achieved SVR. Conclusions: Approximately 70% of treatment-naïve patients with HCV G1 infection undergoing triple therapy with boceprevir in German real-life experience an EVR which allow shortage of triple therapy to 24 weeks. In addition, achieving EVR is associated with a high

EOT response rate > 90%. The higher virologic response at the end of lead-in suggests a higher sensitivity to PegIFN/RBV backbone in pts who achieve EVR. Disclosures: Peter Buggisch – Advisory Committees or Review Panels: Janssen, AbbVie, BMS, Siemens; Speaking and Teaching: Roche, MSD, Gilead Gerlinde Teuber buy Pembrolizumab – Advisory Committees or Review Panels: MSD, Gilead; Grant/ Research Support: MSD, Roche Pharma;

Speaking and Teaching: MSD, Gilead, Janssen, BMS Michael R. R. Kraus – Advisory Committees or Review Panels: Merck/MSD, Roche, Gilead, BMS, Janssen, ABBVIE; Consulting: Merck/MSD, Roche; Speaking and Teaching: Merck/MSD, Gilead, BMS, Janssen, ABBVIE Bernd Weber – Advisory Committees or Review Panels: Molteni Farmaceutici, Bristol Myers Squibb, AbbVie; Speaking and Teaching: Roche Pharma AG, Janssen Cilag, Reckitt Benckiser, Sandoz, Lundbeck Pharma, Sanofi-Aventis, MSD, Gilead Sciences Uwe Naumann – Speaking and Teaching: MSD, Roche, BMS, Abbott, VIIV, Jans-sen, Boehringer Ingelheim, Gilead Dagmar Hartmann – Employment: MSD Germany Bernd Dreher – Employment: MSD Manfred Bilzer – Consulting: MSD Germany The following people have nothing to disclose: Hanns F. Loehr, Hermann Stef-fens, Christine John, Peter R. Geyer, Thomas Witthoeft, Andreas Herrmann, Mark Hoesl, Elmar Zehnter Background: An estimated 25% of HIV infected patients in the United States and 10-50% worldwide are co-infected with HCV. Compared to HCV mono-infected patients, co-infected patients experience decreased ability to spontaneously clear HCV, accelerated liver fibrosis progression leading to earlier liver failure, and higher risk of death.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>